Eton Pharmaceuticals, Inc. (ETON)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total net revenues | 18,928 | 17,282 | 10,324 | 9,074 |
| License | - | - | - | - |
| Product Sales And Royalties | 7,004 | - | - | - |
| Total cost of sales | 7,004 | 7,421 | 4,022 | 3,448 |
| Gross profit | 11,924 | 9,861 | 6,302 | 5,626 |
| Research and development | 3,712 | 1,161 | 505 | 2,970 |
| General and administrative | 9,687 | 9,170 | 5,288 | 5,591 |
| Total operating expenses | 13,399 | 10,331 | 5,793 | 8,561 |
| Loss from operations | -1,475 | -470 | 509 | -2,935 |
| Interest and other expense, net | -1,044 | -1,028 | -8 | -52 |
| Us-gaap_nonoperatingincomeexpense | - | - | -8 | -52 |
| Loss before income tax expense | -2,519 | -1,498 | 501 | -2,987 |
| Income tax expense | 66 | 74 | -126 | 54 |
| Net loss | -2,585 | -1,572 | 627 | -3,041 |
| Diluted eps | - | - | 0.02 | -0.12 |
| Diluted average shares | - | - | 26,550 | 25,778 |
| Net loss per share, basic and diluted (in dollars per share) | -0.1 | -0.06 | 0.02 | -0.12 |
| Weighted average number of common shares outstanding, basic and diluted (in shares) | 26,893,000 | 26,886,000 | 25,900 | 25,778 |